Meeting
2018 ASCO Annual Meeting
Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
Authors
Julie Marie Collins
National Cancer Institute, Bethesda, MD
Julie Marie Collins , Christopher Ryan Heery , Renee Nicole Donahue , Claudia Palena , Ravi Amrit Madan , Julius Strauss , Margaret Elena Gatti-Mays , Jeffrey Schlom , James L. Gulley , Marijo Bilusic
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Other
Clinical Trial Registration Number
NCT02536469
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3091)
DOI
10.1200/JCO.2018.36.15_suppl.3091
Abstract #
3091
Poster Bd #
305
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.
First Author: Nashat Y. Gabrail
Poster
2018 ASCO Annual Meeting
Regorafenib and nivolumab combination therapy for advanced and metastatic solid tumors: Phase I clinical trial (EPOC1603).
First Author: Shota Fukuoka
First Author: Igor Tsaur
Poster
2023 ASCO Annual Meeting
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.
First Author: Yelena Y. Janjigian